75

SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer.

Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, Lilleby W, Meidahl Petersen P, Mirtti T, Pettersson A, Rannikko A, Thellenberg C, Akre O.

Scand J Urol. 2018

SPCG-15

Abstract

74

Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.

Ebbinge M, Berglund A, Varenhorst E, Hedlund PO, Sandblom G; Scandinavian Prostate Cancer Group (SPCG)-5 Study Group.

BJU Int. 2018

SPCG-5

Abstract

73

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.

Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12

Eur Urol. 2018

SPCG-12

Abstract

72

Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.

Sophie D. Fossa, Fredrik Wiklund, Olbjørn Klepp, Anders Angelsen, Arne Solberg, Jan-Erik Damber, Morten Hoyer, Anders Widmark on behalf of the The Scandinavian Prostate Cancer Group-7 Investigators.

Eur Urol. 2016

Abstract

71

Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients.

Klaff R, Varenhorst E, Berglund A, Hedlund PO, Sjöberg F, Sandblom G. SPCG-5 Study Group.

Scand J Urol. 2016

SPCG-5

Abstract

70

Radiation Therapy Did Not Induce Long-Term Changes in Rectal Mucosa: Results From the Randomized Scandinavian Prostate Cancer Group 7 Trial.

Slagsvold JE, Viset T, Wibe A, Kaasa S, Widmark A, Lund JÅ.

Int J Radiat Oncol Biol Phys. 2016

Abstract

69

Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases.

Klaff R, Berglund A, Varenhorst E, Hedlund PO, Jǿnler M, Sandblom G. Scandinavian Prostate Cancer Group (SPCG) Study No. 5.

BJU Int. 2016

SPCG-5

Abstract

68

Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.

Varenhorst E, Klaff R, Berglund A, Hedlund PO, Sandblom G. Scandinavian Prostate Cancer Group (SPCG) Trial No. 5.

Cancer Med. 2016

SPCG-5

Abstract

67

Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: Analysis of the placebo arm of the SPCG-6 study.

Thomsen FB, Brasso K, Berg KD, Gerds TA, Johansson JE, Angelsen A, Tammela TL, Iversen P. Scandinavian Prostate Cancer Group.

Ann Oncol. 2016

SPCG-6

Abstract

66

Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer; long-term follow up of the SPCG-6 study.

Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TL, Iversen P. Scandinavian Prostate Cancer Group.

Eur J Cancer. 2015

SPCG-6

Abstract